{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 45,
  "pageCount": 56,
  "prevPage": 44,
  "nextPage": 46,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a structured comparison between preclinical and clinical assets, with a specific callout for the lead asset (Naporafenib).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/45",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-45",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.38,
        "x": 0.6,
        "y": 0.76
      },
      "kind": "disclaimer",
      "text": "1 Belvarafenib is also being evaluated... 2 Tovorafenib is in Ph 3... 3 Exarafenib in Ph 1b... ORR: overall response rate; SOC: standard of care; PoC: proof-of-concept",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a8e8364-401c-4939-9972-230450ab46ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.8,
        "w": 0.58,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "framework",
      "text": "Preclinical vs Clinical landscape",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5951e8f5-e7e2-428e-95aa-1b74c0be309b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.6,
        "y": 0.62
      },
      "kind": "list",
      "text": "Strong complementarity with Erasca pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b77ba6f-8658-4250-bcac-742a055fe297",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.6,
        "y": 0.43
      },
      "kind": "list",
      "text": "PoC established in NRASm melanoma and RAS Q61X solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d507782d-8ce4-4cbc-94cc-b6cbb317a08f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.38,
        "x": 0.6,
        "y": 0.22
      },
      "kind": "list",
      "text": "Most advanced pan-RAF inhibitor; Dosed in 500+ patients; Potential first-to-market",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee051f2f-ea22-46b6-ae98-f6c3213c7eb7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Naporafenib: Potential first-in-class pan-RAF inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92d60800-cca4-4de3-9b60-e2d280a45a3d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "9ae8f926-3446-4c1f-97b0-02909c3f180c",
      "evidence": "Structured comparison of preclinical vs clinical assets",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}